2024
Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy
Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G, Knowlton C, Jairam V, Campbell A, Park H. Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy. Advances In Radiation Oncology 2024, 9: 101500. PMID: 38699671, PMCID: PMC11063223, DOI: 10.1016/j.adro.2024.101500.Peer-Reviewed Original ResearchLocal recurrence-free survivalNon-lung primaryAssociated with higher local recurrence-free survivalProgression-free survivalBiologically effective doseLocal controlRadioresistant metastasesOverall survivalPulmonary metastasesPrimary cancerColorectal carcinomaAssociated with superior local controlMultivariate analysisPatients treated with radiotherapyRisk of local recurrenceMedian follow-up timeMultivariable Cox proportional hazards regressionInferior local controlMedian total doseSuperior local controlAssociated with decreased riskImpact of histologyMetastasis-free survivalRecurrence-free survivalLocal failureDose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-volume Predictors of Radiation Pneumonitis Following Thoracic Hypofractionated Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e5. DOI: 10.1016/j.ijrobp.2023.10.054.Peer-Reviewed Original ResearchHypofractionated radiation therapyRisk of gradeUltra-central tumoursRadiation pneumonitisLung V20Lung V5Central tumorsMultivariable logistic regression analysisSingle health care systemDose-volume predictorsDosimetric risk factorsGrade 5 toxicitySimilar local controlDose-fractionation regimensProbability of gradeProximal tracheobronchial treeLogistic regression analysisMATERIAL/METHODSHealth care systemPrimary endpointOverall survivalHypofractionated radiotherapyMultivariable analysisLung doseThoracic tumorsDosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax
Sasse, Oh P, Saeed N, Yang D, Peters G, Hayman T, Housri N, Laird J, Campbell A, Knowlton C, Park H. Dosimetric Factors Associated with Esophagitis Following Hypofractionated Radiotherapy to the Thorax. International Journal Of Radiation Oncology • Biology • Physics 2024, 118: e7-e8. DOI: 10.1016/j.ijrobp.2023.10.059.Peer-Reviewed Original ResearchHypofractionated radiation therapyTotal patientsOverall survivalLocal controlUltra-central lung tumorsMultivariable logistic regression analysisSignificant differencesComparable local controlGrade 3 esophagitisRisk of gradeCases of gradeProbability of gradeLogistic regression analysisMATERIAL/METHODSMean esophagus doseSingle healthcare systemEsophagus DmaxPrimary endpointHypofractionated radiotherapyDosimetric factorsMultivariable analysisEsophagus doseThoracic tumorsDosimetric variablesClinical trials
2023
Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy
Sasse A, Oh P, Saeed N, Yang D, Hayman T, Knowlton C, Peters G, Campbell A, Laird J, Housri N, Park H. Dose-Volume Predictors of Radiation Pneumonitis After Thoracic Hypofractionated Radiation Therapy. Practical Radiation Oncology 2023, 14: e97-e104. PMID: 37984711, DOI: 10.1016/j.prro.2023.11.006.Peer-Reviewed Original ResearchMean lung doseHypofractionated radiation therapyRisk of gradeRadiation pneumonitisLung V20Lung V5Dose-volume predictorsDosimetric risk factorsLogistic regression analysisGrade 5 casesSingle healthcare systemPrimary endpointDose regimensMultivariable analysisLung doseThoracic tumorsDosimetric variablesRisk factorsPneumonitisRadiation therapyCommon treatmentClinical practicePatientsSignificant associationPotential predictorsResponse time of high impact factor medical journals versus an expert-curated, online oncology platform before and during the COVID-19 pandemic.
Lubas M, Lukez A, Henry E, Housri N, Egleston B, Howell K. Response time of high impact factor medical journals versus an expert-curated, online oncology platform before and during the COVID-19 pandemic. JCO Oncology Practice 2023, 19: 465-465. DOI: 10.1200/op.2023.19.11_suppl.465.Peer-Reviewed Original ResearchDose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations
Sasse A, Saeed N, Oh P, Housri N, Knowlton C, Hayman T, Peters G, Campbell A, Yang D, Park H. Dose-Escalated vs. Conventional Hypofractionated Radiotherapy for Lung Cancer Patients in Predominantly Central Locations. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e55. DOI: 10.1016/j.ijrobp.2023.06.768.Peer-Reviewed Original ResearchStereotactic body radiotherapyUltra-central tumoursHypofractionated radiation therapyHigh local controlOverall survivalGrade 3Local controlLung cancerNon-small cell lung cancerPromising local controlOutcomes of patientsEffective treatment regimenCell lung cancerHigher overall survivalLung cancer patientsMATERIAL/METHODSMedian ageHypofractionated radiotherapyTreatment regimenBody radiotherapyBaseline variablesCancer patientsTreatment optionsTumor locationChi-square analysisSurvival Outcomes for Oligometastatic vs. Polymetastatic Extensive-Stage Small Cell Lung Cancer Following Consolidative Thoracic Radiotherapy
Verma N, Ninia J, Hayman T, Housri N, Peters G, Knowlton C, Campbell A, Park H. Survival Outcomes for Oligometastatic vs. Polymetastatic Extensive-Stage Small Cell Lung Cancer Following Consolidative Thoracic Radiotherapy. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: e68-e69. DOI: 10.1016/j.ijrobp.2023.06.797.Peer-Reviewed Original ResearchLocal recurrence-free survivalProgression-free survivalES-SCLC patientsES-SCLCOligometastatic diseaseOligometastatic patientsImproved OSLung involvementExtensive-stage small-cell lung cancerMultivariable Cox proportional hazards regressionMultivariable Cox regression analysisCox proportional hazards regressionSmall cell lung cancerBilateral lung involvementConsolidative thoracic radiotherapyLimited metastatic burdenMetastasis-directed radiotherapyPlatinum-doublet chemotherapyCox regression analysisMetastasis-free survivalRecurrence-free survivalTime of diagnosisProportional hazards regressionCell lung cancerLog-rank testLaunching the Mednet in Pulmonary Medicine: An Online Platform for Expert Answers to Real World Clinical Questions
Khan A, Housri N, Briones M. Launching the Mednet in Pulmonary Medicine: An Online Platform for Expert Answers to Real World Clinical Questions. 2023, a4286-a4286. DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a4286.Peer-Reviewed Original Research
2022
Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology
Ciuro J, Henry E, Housri N, Banerjee R, Brem E, Brooks T, Derman B, Hill B, Hofmeister C, Lunning M, Matasar M, Phillips T, Rutherford S, Zanwar S, Lee L. Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology. Blood 2022, 140: 13180-13181. DOI: 10.1182/blood-2022-167959.Peer-Reviewed Original ResearchGender analysis of oncology expert participation on online professional platforms.
Kunzman J, Henry E, Housri N, Kamran S, Kunz P, Lee L, LoConte N, Burt L. Gender analysis of oncology expert participation on online professional platforms. Journal Of Clinical Oncology 2022, 40: 350-350. DOI: 10.1200/jco.2022.40.28_suppl.350.Peer-Reviewed Original Research
2020
Using a Collaborative, Virtual Discussion Platform to Mobilize Oncologic Expertise for the COVID-19 Pandemic.
Bejjani A, Burt L, Washington C, Terao M, Housri S, Housri N. Using a Collaborative, Virtual Discussion Platform to Mobilize Oncologic Expertise for the COVID-19 Pandemic. JCO Clinical Cancer Informatics 2020, 4: 794-798. PMID: 32897736, PMCID: PMC7529517, DOI: 10.1200/cci.20.00073.Peer-Reviewed Original ResearchConceptsGynecologic oncologyPediatric oncologyActive disease sitesCOVID-19 pandemicOncology patientsMedical oncologyClinical managementBreast cancerOncology expertsCare resourcesInitial experienceDisease sitesDisease typeOncologyWorldwide pandemicOncologistsRadiation oncologyHealth careCOVID-19Peer-reviewed informationSubstantial numberPandemicTotal numberPatientsCancerProvider Engagement in Radiation Oncology Data Science: Workshop Report.
Jain AK, Aneja S, Fuller CD, Dicker AP, Chung C, Kim E, Kirby JS, Quon H, Lam CJK, Louv WC, Ahern C, Xiao Y, McNutt TR, Housri N, Ennis RD, Kang J, Tang Y, Higley H, Berny-Lang MA, Camphausen KA. Provider Engagement in Radiation Oncology Data Science: Workshop Report. JCO Clinical Cancer Informatics 2020, 4: 700-710. PMID: 32755458, PMCID: PMC7469584, DOI: 10.1200/cci.20.00051.Peer-Reviewed Original Research
2019
Results of a pilot/phase II study of gamma knife radiosurgery for brain metastases and implications for future prospective clinical trials
Yu J, Singh C, Bindra R, Contessa J, Husain Z, Hansen J, Park H, Roberts K, Bond J, Tien C, Guo F, Colaco R, Housri N, Magnuson W, Mahajan A, Omay S, Chiang V. Results of a pilot/phase II study of gamma knife radiosurgery for brain metastases and implications for future prospective clinical trials. Journal Of Radiation Oncology 2019, 8: 39-46. DOI: 10.1007/s13566-018-0370-7.Peer-Reviewed Original ResearchYale-New Haven HospitalPhase II studyBrain metastasesClinical trialsII studyKnife radiosurgeryLocal controlPre-defined primary endpointWhole-brain radiation treatmentFuture prospective clinical trialsEvaluable brain metastasesSymptomatic radiation necrosisMedian patient ageLocal control ratePhase 2 studyGood local controlProspective clinical trialsNumber of metastasesLarge clinical trialsProportional hazards regressionFuture clinical trialsGamma knife radiosurgeryImportant clinical variablesStandard clinical practiceNew Haven Hospital
2018
A Pilot/Phase II Study of Stereotactic Radiosurgery for Brain Metastases Using Rational Dose Selection
Yu J, Singh C, Bindra R, Contessa J, Husain Z, Hansen J, Park H, Roberts K, Bond J, Tien C, Guo F, Colaco R, Housri N, Magnuson W, Omay B, Chiang V. A Pilot/Phase II Study of Stereotactic Radiosurgery for Brain Metastases Using Rational Dose Selection. International Journal Of Radiation Oncology • Biology • Physics 2018, 102: e372-e373. DOI: 10.1016/j.ijrobp.2018.07.1113.Peer-Reviewed Original ResearchDissemination of breast cancer knowledge and expertise from NCI-CCC tumor boards with community oncologists.
Kalra M, Karuturi M, Jankowitz R, McCann K, Wei M, Mougalian S, Tripathy D, Brufsky A, Barcenas C, Hurvitz S, Peddi P, Henry N, Housri S, Housri N. Dissemination of breast cancer knowledge and expertise from NCI-CCC tumor boards with community oncologists. Journal Of Clinical Oncology 2018, 36: e18575-e18575. DOI: 10.1200/jco.2018.36.15_suppl.e18575.Peer-Reviewed Original Research
2017
Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice
Rosenberg SA, Baschnagel AM, Bagley SJ, Housri N. Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice. Current Oncology Reports 2017, 19: 5. PMID: 28168606, DOI: 10.1007/s11912-017-0563-z.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyNon-small cell lung cancer (NSCLC) treatmentCell lung cancer treatmentLung cancer treatmentNational clinical trialEvidence-based treatmentsEvidence-based medicineTranslating EvidenceCommunity oncologistsBody radiotherapyLung cancerClinical trialsPreclinical discoveryClinical practiceCommunity settingsCancer treatmentOncologistsCommunity practiceTreatmentMedicineImmunotherapyNSCLCInternet-based resourcesRadiotherapyCancer
2016
Sharing Experiential Knowledge and Clinical Evidence in an Online Radiation Oncology Social Network
Housri N, Ye J, Lucas J, Green G, Baschnagel A, Burt L, Dan T, Mancini B, Lloyd S, Housri S. Sharing Experiential Knowledge and Clinical Evidence in an Online Radiation Oncology Social Network. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e417. DOI: 10.1016/j.ijrobp.2016.06.1678.Peer-Reviewed Original ResearchWill academic and community physicians engage and share knowledge in an online physician social network? Lessons from the Radiation Oncology Community
Housri N, Burt L, Lucas J, Housri S. Will academic and community physicians engage and share knowledge in an online physician social network? Lessons from the Radiation Oncology Community. Journal Of Clinical Oncology 2016, 34: e18200-e18200. DOI: 10.1200/jco.2016.34.15_suppl.e18200.Peer-Reviewed Original Research
2015
Racial Disparities in Hypofractionated Radiotherapy Breast Cancer Clinical Trials
Housri N, Khan AJ, Taunk N, Goyal S, Nelson CJ, Ferro A, Haffty BG. Racial Disparities in Hypofractionated Radiotherapy Breast Cancer Clinical Trials. The Breast Journal 2015, 21: 387-394. PMID: 25919123, DOI: 10.1111/tbj.12419.Peer-Reviewed Original ResearchConceptsBreast cancer patientsNon-white womenCancer patientsClinical trialsWhite womenRacial disparitiesRadiation oncology clinical trialsBreast cancer clinical trialsRetrospective cohort studyClinico-pathologic factorsLymph node positivityUse of chemotherapyClinical trial enrollmentOncology clinical trialsUse of brachytherapyBreast radiotherapy trialsCancer clinical trialsPaucity of dataCohort studyNode positivityPatient demographicsReceptor statusTrial enrollmentTumor characteristicsDisease stage
2014
Significance of Phospho(Ser73)-K8 Expression in Women With Breast Cancer of Triple Negative Phenotype
Garg R, Housri N, Kongara S, Wu H, Schiff D, Moran M, Karantza V, Haffty B. Significance of Phospho(Ser73)-K8 Expression in Women With Breast Cancer of Triple Negative Phenotype. International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s69-s70. DOI: 10.1016/j.ijrobp.2014.05.230.Peer-Reviewed Original Research